Voriconazole Treatment Effect on Pediatric Patients: Retrospective Analysis
the Cancer Therapy Advisor take:
It is established that the use of voriconazole as an antifungal agent is associated with an increased risk of a number of cutaneous reactions such as skin cancer, phototoxicity, and accelerated photo-aging in adults.
Researchers sought to identify the risk for these adverse reactions in children, as those factors have not yet been clearly established. The researchers conducted a retrospective analysis of 430 pediatric patients from Boston Children’s Hospital who had received voriconazole between 2003 and 2013.
The researchers found that 20% of all children who received voriconazole displayed phototoxicity and 47% of children who received voriconazole for 6 months or longer experienced phototoxicity. The researchers also determined that cystic fibrosis, cumulative dose, cumulative treatment time, and white race were associated with phototoxicity.
In all patients analyzed, four experienced nonmelanoma skin cancer. In patients who experienced phototoxicity, 5% discontinued their voriconazole treatment, 6% were referred to a dermatologist, and 26% were counseled by their primary physician regarding sun protection.
The research results are limited in that the design of the study is retrospective and there is a potential for referral bias given the fact that the study was limited to a single center. Based on their findings, the researchers concluded that photoxicity in children who were treated with voriconazole is relatively common and has the potential to lead to nonmelanoma skin cancer.
Phototoxicity cause by voriconazole is somewhat common in children and may lead to nonmelanoma skin cancer in some.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models